Physician
Rodrigo Argenal MD PA
Rodrigo Argenal MD PA was paid $4.50M by Medicaid between Jul 2019 and Dec 2024, across 71 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 21% of everything it billed.
33Billing provider infoRODRIGO ARGENAL MD PA
EDINBURG, TX 78539
EDINBURG, TX 78539
33aNPI1780916585assigned 02/03/2010
33bProvider typeFamily Medicine Physician
28Total paid$4.50M
24GClaims217,772
24DCodes billed71
24AFirst – last monthJul 2019 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in Texas
Rank by total paid#22 of 1,204
Median peer was paid$31K
This provider vs. median146×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 101 | $2K | |
| 2020 | 8,247 | $139K | |
| 2021 | 42,521 | $921K | |
| 2022 | 57,967 | $1.23M | |
| 2023 | 61,405 | $1.24M | |
| 2024incomplete | 47,531 | $967K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 21% | 27,533 | 23,520 | $931K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 16% | 15,808 | 13,789 | $737K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 13% | 16,418 | 14,747 | $603K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 9.2% | 33,141 | 14,836 | $414K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 7.2% | 4,529 | 4,368 | $323K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 5.4% | 19,317 | 16,904 | $242K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 5.1% | 3,190 | 2,997 | $228K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 4.7% | 2,833 | 2,736 | $213K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 4.2% | 18,877 | 8,160 | $191K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.5% | 2,614 | 2,165 | $112K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.1% | 15,893 | 14,413 | $95K |
| 99429 | 1.5% | 2,025 | 1,985 | $65K |
59 more codes
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 1.4% | 860 | $65K |
| 87634 | 1.4% | 1,224 | $61K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.2% | 8,964 | $56K |
| 87807 | <1% | 4,056 | $41K | |
| 90461 | <1% | 11,812 | $29K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 679 | $28K |
| 99000 | <1% | 3,457 | $26K | |
| 83655 | <1% | 626 | $6K | |
| 92558 | <1% | 766 | $5K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 571 | $5K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 405 | $4K |
| 81002 | <1% | 1,293 | $3K | |
| 86769 | <1% | 92 | $3K | |
| 92552 | <1% | 341 | $2K | |
| 99381 | <1% | 39 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 137 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 140 | $1K |
| 0071A | <1% | 33 | $1K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 19 | $1K |
| 0072A | <1% | 30 | $1K | |
| 0001A | <1% | 49 | $930.02 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 13 | $848.25 |
| 36410 | <1% | 44 | $589.20 | |
| 0111A | <1% | 15 | $520.00 | |
| 96160 | <1% | 1,125 | $460.73 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 17 | $446.18 |
| 90677 | <1% | 487 | $254.76 | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 42 | $200.00 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 12 | $187.68 |
| 99050 | <1% | 14 | $137.54 | |
| 99051 | <1% | 222 | $136.50 | |
| 90686 | <1% | 1,868 | $40.05 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 417 | $24.50 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 55 | $21.12 |
| 36416 | <1% | 7,354 | $3.50 | |
| 90656 | <1% | 271 | $0.01 | |
| 90633 | 0% | 800 | $0.00 | |
| 90670 | 0% | 1,876 | $0.00 | |
| 90648 | 0% | 1,578 | $0.00 | |
| 90685 | 0% | 620 | $0.00 | |
| 90681 | 0% | 675 | $0.00 | |
| 99177 | 0% | 467 | $0.00 | |
| 90707 | 0% | 94 | $0.00 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 19 | $0.00 |
| 90700 | 0% | 110 | $0.00 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 25 | $0.00 |
| 99173 | 0% | 118 | $0.00 | |
| 91311 | 0% | 12 | $0.00 | |
| 90734 | 0% | 26 | $0.00 | |
| 90710 | 0% | 44 | $0.00 | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | 0% | 54 | $0.00 |
| 90698 | 0% | 38 | $0.00 | |
| 90716 | 0% | 94 | $0.00 | |
| 90723 | 0% | 964 | $0.00 | |
| 90696 | 0% | 32 | $0.00 | |
| 36415 | Collection of venous blood by venipuncture | 0% | 173 | $0.00 |
| 90651 | 0% | 36 | $0.00 | |
| 90647 | 0% | 75 | $0.00 | |
| 96127 | 0% | 115 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialARGENAL, RODRIGO (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Arbe Professional Services of Texas Series, LLC | San Juan, TX | $178K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.